Taking Account of Inobservable Periods in Longitudinal Drug Treatment Follow-up

CompletedOBSERVATIONAL
Enrollment

171,861

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Drug Exposition
Interventions
OTHER

Exposition to hypnotics or anxiolytics benzodiazepines

"Exposition to at least one drug belonging to the following classes during the last 12 months before index date :~* Benzodiazepine derivatives (N05BA)~* Benzodiazepine derivatives (N05CD)~* Benzodiazepine related drugs (N05CF)"

OTHER

Exposition to non benzodiazepines antidepressants, hypnotics or anxiolytics

"Exposition to at least one drug belonging to the following classes during the last 12 months before index date :~* Antipsychotics (N05A)~* Antiepileptics with the exception of clonazepam (N03)~* Drugs used for alcohol dependance (N07BB)~* Drugs used for opioids dependance (N07BC)"

OTHER

Medical consultation without prescription

Medical consultation without prescription of any drugs of interest

OTHER

Administrative and medical data

"* Gender~* Birthdate~* Department of residence~* City of residence~* Vital status (month and date of death)~* Affiliation to Universal Health Coverage~* Number of chronic long-term illness, medical diagnostic or pathology (CIM 10 code), onset and end dates~* Drugs reimbursements (Date of care onset, drugs identification code, number of box delivered)~* Data collected from medicalisation program of information system and private and public home care structures~* Medical consultations, medical acts ( Common Classification of Medical Acts nomenclature)"

All Listed Sponsors
lead

University Hospital, Toulouse

OTHER

NCT02827331 - Taking Account of Inobservable Periods in Longitudinal Drug Treatment Follow-up | Biotech Hunter | Biotech Hunter